Related Experiment Videos
The dendritic cell system and anti-tumour immunity
1Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Headington, U.K.
In Vivo (Athens, Greece)
|May 1, 1993
Summary
Dendritic cells (DCs) initiate immune responses, unlike other antigen-presenting cells (APCs) that can cause tolerance. This review explores using DCs for cancer vaccination to overcome tumor-induced immune unresponsiveness.
Area of Science:
- Immunology
- Cell Biology
- Cancer Research
Background:
- Dendritic cells (DCs) are crucial for initiating T-cell dependent immune responses.
- DCs process and present antigens, delivering activation signals to T cells.
- Other antigen-presenting cells (APCs) can induce peripheral T-cell tolerance.
Purpose of the Study:
- To review the immunobiology of dendritic cells (DCs).
- To explore the potential of DCs in cancer immunotherapy.
- To investigate overcoming immune unresponsiveness in tumor-bearing hosts.
Main Methods:
- Literature review of dendritic cell (DC) immunobiology.
- Analysis of T-cell anergy in tumor-bearing hosts.
- Evaluation of DC-based vaccination strategies for cancer.
Main Results:
- DCs are key initiators of adaptive immunity.
- Tumor-induced immune unresponsiveness may stem from T-cell clonal anergy.
- DC-based vaccination holds promise for cancer treatment.
Conclusions:
- Dendritic cells (DCs) play a pivotal role in immune activation.
- Understanding DC function is critical for developing effective cancer vaccines.
- Harnessing DCs may overcome tumor-induced immune suppression and promote cancer rejection.